Skip to main content

Valsartan Recall Lawsuit Set for Trial

Valsartan Recall Lawsuit Set for Trial

Valsartan Recall Lawsuit Set for Trial

Introduction

Years after the initiation of Valsartan recalls, the U.S. District Judge overseeing lawsuits filed by individuals harmed by tainted versions of the blood pressure drug has been approved the first case to proceed to trial.

Over 1,200 valsartan recall lawsuits have been lodged against manufacturers and distributors, alleging that alterations to the generic drug manufacturing process resulted in the distribution of pills containing elevated levels of harmful chemicals like N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), known to elevate the risk of various cancers and other injuries.

Centralizing the litigation before a U.S. District Judge in the District of New Jersey since 2019, the parties have been preparing for early "bellwether" trials to assess how juries might respond to consistent evidence and testimony across numerous claims. However, given the prolonged latency period for certain cancers associated with NDMA in valsartan, new lawsuits continue to emerge.

Originally slated to commence on March 18, the first valsartan trial was postponed by a text order entered on the docket on March 8, without a subsequent explanation or new trial date being established. Subsequently, on March 26, the Judge denied the manufacturers' motion for summary judgment in the trial case, permitting claims for breach of express warranty, consumer protection laws, and fraud to proceed. Additionally, the Judge declined to preclude plaintiffs from seeking punitive damages against the manufacturers and distributors, potentially resulting in significantly higher damages to hold the manufacturers accountable for disregarding consumer health and safety.

Should the parties fail to make headway toward resolving the litigation or implementing a Valsartan recall settlements program, it is anticipated that the Judge will proceed with a series of "bellwether" trials. Following this, he may consider remanding numerous claims back to U.S. District Courts across the nation for separate trial dates in the future.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors

Categories: E-Cigarette: JUUL

As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.

A study published in Environmental Health Perspectives in…

Appeals Court Upholds $611M Roundup Verdict

Categories: Roundup

A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.

The case involved three plaintiffs from New…

Valsartan “Wave 2” Bellwether Trial Schedule Set by Court

Categories: Valsartan

As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.

This move comes in anticipation of the possibility that parties may…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!